| Recruiting | A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3C NCT07347600 | Hoffmann-La Roche | — |
| Not Yet Recruiting | SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breas NCT07307287 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Recruiting | Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer NCT07085767 | Olema Pharmaceuticals, Inc. | Phase 3 |
| Recruiting | A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Ca NCT07024173 | Shandong Suncadia Medicine Co., Ltd. | Phase 3 |
| Recruiting | Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline Dur NCT06727773 | UNC Lineberger Comprehensive Cancer Center | Phase 2 |
| Recruiting | A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combinati NCT06827236 | BioNTech SE | Phase 1 / Phase 2 |
| Active Not Recruiting | Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Co NCT06449222 | BioNTech SE | Phase 2 |
| Active Not Recruiting | A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab a NCT07386938 | R-Pharm | Phase 3 |
| Not Yet Recruiting | Predicting Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer NCT06499168 | Assiut University | — |
| Recruiting | Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer NCT06220214 | Alison Stopeck | EARLY_Phase 1 |
| Recruiting | A Study of Pembrolizumab and Cryoablation in People With Breast Cancer NCT06246968 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adu NCT05963984 | Carrick Therapeutics Limited | Phase 2 |
| Completed | A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative NCT05963997 | Carrick Therapeutics Limited | Phase 1 / Phase 2 |
| Recruiting | The Choice of Treatment Methods and Efficacy of LABC NCT06080620 | Peking Union Medical College Hospital | N/A |
| Terminated | Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pert NCT05744375 | Spanish Breast Cancer Research Group | Phase 2 |
| Recruiting | A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC. NCT06064812 | Forward Pharmaceuticals Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Breast Cancer Exercise Intervention Study NCT05957068 | National Cancer Centre, Singapore | N/A |
| Unknown | Influence of Intermittent Fasting on Locally Advanced Breast Cancer Patients NCT06174259 | Menoufia University | N/A |
| Recruiting | To Evaluate the Efficacy and Safety of Ipsilateral Supraclavicular Lymph Node Dissection for Breast Cancer Pat NCT06605521 | Henan Cancer Hospital | — |
| Unknown | Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy NCT05809024 | Yongsheng Wang | Phase 4 |
| Completed | Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole NCT05163106 | University Hospital, Akershus | Phase 2 |
| Recruiting | Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy NCT05582499 | Fudan University | Phase 2 |
| Active Not Recruiting | Onvansertib + Paclitaxel In TNBC NCT05383196 | Antonio Giordano, MD | Phase 1 / Phase 2 |
| Recruiting | Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmocicli NCT05508906 | Olema Pharmaceuticals, Inc. | Phase 1 |
| Completed | A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Tra NCT05415215 | Hoffmann-La Roche | Phase 3 |
| Completed | Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to H NCT05217381 | MedSIR | — |
| Withdrawn | Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC NCT05233696 | University of Colorado, Denver | Phase 2 |
| Unknown | Neoadjuvant Inetetamab Combined With Pertuzumab and Paclitaxel/Carboplatin for Breast Cancer NCT05749016 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Completed | Efficacy and Safety of Tenalisib (RP6530), in Patients With Locally Advanced or Metastatic Breast Cancer NCT05021900 | Rhizen Pharmaceuticals SA | Phase 2 |
| Completed | Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors NCT05002868 | Rhizen Pharmaceuticals SA | Phase 1 |
| Unknown | ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study) NCT04669587 | EnhancedBio USA Inc. | Phase 1 / Phase 2 |
| Completed | A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer NCT04699630 | SCRI Development Innovations, LLC | Phase 2 |
| Unknown | NEOZOL_Follow-up Study NCT04899713 | Hospices Civils de Lyon | — |
| Completed | HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Br NCT03685331 | Abramson Cancer Center at Penn Medicine | Phase 1 |
| Completed | Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/ NCT04352777 | Duke University | Phase 2 |
| Active Not Recruiting | Three Fraction Radiation to Induce Immuno-Oncologic Response NCT03978663 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | N/A |
| Recruiting | PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer NCT04360941 | Royal Marsden NHS Foundation Trust | Phase 1 |
| Completed | COVID-19 Pandemic: Effect on Management of Patients With Breast Cancer NCT04929964 | Mehwish Mooghal , MBBS | — |
| Recruiting | Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer NCT04254263 | RenJi Hospital | Phase 3 |
| Terminated | Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive B NCT04042051 | Cancer Trials Ireland | Phase 1 |
| Withdrawn | Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer NCT04088032 | Alison Stopeck | EARLY_Phase 1 |
| Unknown | Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Recepto NCT04318223 | Consorzio Oncotech | Phase 2 |
| Unknown | Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients NCT03924466 | Universitair Ziekenhuis Brussel | Phase 2 |
| Terminated | Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer NCT03329378 | Icahn School of Medicine at Mount Sinai | Phase 2 |
| Completed | CTC in Predicting Neoadjuvant Chemotherapy Among LABC Patients: a Single-center, Prospective, Exploratory Clin NCT03732339 | RenJi Hospital | N/A |
| Active Not Recruiting | Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy For Locally Advanced Breast Cancer NCT03255577 | Memorial Sloan Kettering Cancer Center | N/A |
| Completed | A Study of Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2 NCT02595762 | Hoffmann-La Roche | — |
| Active Not Recruiting | The p53 Breast Cancer Trial NCT02965950 | Haukeland University Hospital | Phase 2 |
| Completed | A Study of the Safety and Effectiveness of Irosustat When Added to an AI in ER+ve Locally Advanced or Metastat NCT01785992 | Imperial College London | Phase 2 |
| Completed | An Open-label, Multi-center Phase Ⅳ Trial to Evaluate the Efficacy and Safety of Sequential Neoadjuvant Chemot NCT01660542 | Yonsei University | Phase 4 |
| Completed | Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Management of Locally Advanced Breas NCT01367288 | Hospices Civils de Lyon | Phase 2 |
| Recruiting | I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer NCT01042379 | QuantumLeap Healthcare Collaborative | Phase 2 |
| Completed | Study of Artesunate in Metastatic Breast Cancer NCT00764036 | Heidelberg University | Phase 1 |
| Completed | Characterization of Circulating Tumor Cells (CTC-s) in Patients With Locally Advanced or Metastatic Stage IV B NCT01048918 | City of Hope Medical Center | — |
| Completed | Using Bio Markers to Predict Disease Recurrence and Cognitive Function in High Risk Breast Ca NCT00756132 | University Health Network, Toronto | — |
| Completed | Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer NCT00623233 | Eli Lilly and Company | Phase 2 |
| Completed | Dynamic Breast MRI in Assessing Locally Advanced Breast Cancer NCT00455273 | Sunnybrook Health Sciences Centre | — |
| Terminated | Monitoring of Neoadjuvant Therapy in Locally-Advanced Breast Cancer NCT01837563 | Dartmouth-Hitchcock Medical Center | — |
| Completed | A Prospective Study to Evaluate FDG-PET, Breast MRI, and Breast Ultrasonography in Monitoring Tumour Responses NCT00788489 | Ontario Clinical Oncology Group (OCOG) | — |
| Terminated | Hydralazine and Valproate Added to Chemotherapy for Breast Cancer NCT00395655 | National Institute of Cancerología | Phase 2 |
| Completed | The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone NCT00065325 | AstraZeneca | Phase 3 |
| Completed | Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women NCT00237133 | Novartis Pharmaceuticals | Phase 4 |